<DOC>
	<DOCNO>NCT02822157</DOCNO>
	<brief_summary>This randomize , open-label , two-arm study patient relapse epithelial ovarian tumor . Patients randomize 1:1 ratio receive olaparib standard chemotherapy possibility crossover time progression .</brief_summary>
	<brief_title>Circulating Tumor DNA Guiding ( Olaparib ) LynparzaÂ® Treatment Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>recurrent epithelial carcinoma ovary , fallopian tube primary peritoneum At least 1 previous line chemotherapy Measurable disease Patients normal organ bone marrow function measure within 28 day randomization WHO 02 Primary platinumrefractory disease Known hypersensitivity olaparib Resting ECG QTc &gt; 470 msec Concomitant use know potent CYP3A4 inhibitor Symptomatic uncontrolled brain metastasis Patients unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>